Overview Dividends

(SMMT) Summit Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86627T1088

Antibody, Immunotherapy, Oncology, Clinical

SMMT EPS (Earnings per Share)

EPS (Earnings per Share) of SMMT over the last years for every Quarter: "2020-09": -1.24, "2020-12": -0.9, "2021-03": -1.05, "2021-06": -1.35, "2021-09": -1, "2021-12": -0.28, "2022-03": -0.22, "2022-06": -0.17, "2022-09": -0.14, "2022-12": -0.07, "2023-03": -1.43, "2023-06": -0.02, "2023-09": -0.03, "2023-12": -0.04, "2024-03": -0.06, "2024-06": -0.09, "2024-09": -0.08, "2024-12": -0.07, "2025-03": -0.0677, "2025-06": -0.12, "2025-09": -0.2315,
EPS Growth (3Y CAGR): -4.47%
EPS Trend (3Y Correlation): 27.5%

SMMT Revenue

Revenue of SMMT over the last years for every Quarter: 2020-09: 0.181, 2020-12: 0.185, 2021-03: 0.192, 2021-06: 0.057, 2021-09: 1.309, 2021-12: 0.251, 2022-03: 0.25, 2022-06: 0.235, 2022-09: 0.22, 2022-12: 0.000705, 2023-03: 0, 2023-06: 0.235, 2023-09: 0, 2023-12: -0.235, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: null,
Revenue Growth (3Y CAGR): -20.06%
Revenue Trend (3Y Correlation): -35.8%

Description: SMMT Summit Therapeutics October 30, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) is a U.S.-based biopharma focused on developing “patient-friendly” medicines, with its flagship candidate ivonescimab-a bispecific antibody that simultaneously blocks PD-1 and anti-angiogenesis pathways-currently in Phase III trials for non-small cell lung cancer (NSCLC). Founded in 2003 and headquartered in Miami, Florida, the company trades as common stock under the ticker SMMT in the Biotechnology sub-industry.

Key metrics that investors watch include the company’s cash runway of roughly $120 million (Q2 2024), which should fund operations into late 2025 assuming current burn rates, and a net loss of $45 million for the most recent twelve-month period, reflecting heavy R&D spend. The NSCLC market is projected to exceed $15 billion by 2028, while bispecific antibodies have seen a 35 % CAGR over the past three years, indicating strong secular tailwinds for ivonescimab’s therapeutic class.

If you’re looking to deepen your analysis, a quick look at Summit’s upcoming Phase III data release schedule and its partnership pipeline on ValueRay could help you gauge near-term catalysts and valuation sensitivity.

SMMT Stock Overview

Market Cap in USD 14,077m
Sub-Industry Biotechnology
IPO / Inception 2015-03-05

SMMT Stock Ratings

Growth Rating 54.5%
Fundamental 45.6%
Dividend Rating -
Return 12m vs S&P 500 -24.4%
Analyst Rating 4.70 of 5

SMMT Dividends

Currently no dividends paid

SMMT Growth Ratios

Growth Correlation 3m -66.1%
Growth Correlation 12m 34.1%
Growth Correlation 5y 45%
CAGR 5y 162.71%
CAGR/Max DD 3y (Calmar Ratio) 2.15
CAGR/Mean DD 3y (Pain Ratio) 4.07
Sharpe Ratio 12m 0.76
Alpha 0.38
Beta -1.137
Volatility 93.16%
Current Volume 2681.7k
Average Volume 20d 3433.8k
Stop Loss 16.9 (-7%)
Signal -1.02

Piotroski VR‑10 (Strict, 0-10) 0.5

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)
FCFTA -0.90 (>2.0%) and ΔFCFTA -61.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.90 (>3.0%) and CFO -235.3m > Net Income -412.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (743.4m) change vs 12m ago 5.02% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.0% (prev -0.07%; Δ 0.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -166.1 (EBITDA TTM -409.3m / Interest Expense TTM 2.46m) >= 6 (WARN >= 3)

Altman Z'' -61.70

(A) 0.69 = (Total Current Assets 246.5m - Total Current Liabilities 64.9m) / Total Assets 261.7m
(B) -7.93 = Retained Earnings (Balance) -2.07b / Total Assets 261.7m
warn (B) unusual magnitude: -7.93 — check mapping/units
(C) -1.36 = EBIT TTM -409.3m / Avg Total Assets 301.8m
(D) -29.80 = Book Value of Equity -2.07b / Total Liabilities 69.5m
Total Rating: -61.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 45.59

1. Piotroski 0.50pt = -4.50
2. FCF Yield -1.70% = -0.85
3. FCF Margin data missing
4. Debt/Equity 0.03 = 2.50
5. Debt/Ebitda 0.57 = 2.25
7. RoE -120.9% = -2.50
8. Rev. Trend -35.79% = -2.68
9. EPS Trend 27.52% = 1.38

What is the price of SMMT shares?

As of November 09, 2025, the stock is trading at USD 18.18 with a total of 2,681,655 shares traded.
Over the past week, the price has changed by -3.86%, over one month by -18.44%, over three months by -35.23% and over the past year by -13.84%.

Is Summit Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Summit Therapeutics (NASDAQ:SMMT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 45.59 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SMMT is around 18.39 USD . This means that SMMT is currently overvalued and has a potential downside of 1.16%.

Is SMMT a buy, sell or hold?

Summit Therapeutics has received a consensus analysts rating of 4.70. Therefore, it is recommended to buy SMMT.
  • Strong Buy: 7
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SMMT price?

Issuer Target Up/Down from current
Wallstreet Target Price 31.5 73%
Analysts Target Price 31.5 73%
ValueRay Target Price 19.4 6.7%

SMMT Fundamental Data Overview November 02, 2025

Market Cap USD = 14.08b (14.08b USD * 1.0 USD.USD)
P/S = 753.9008
P/B = 59.7567
Beta = -1.137
Revenue TTM = 0.0 USD
EBIT TTM = -409.3m USD
EBITDA TTM = -409.3m USD
Long Term Debt = 5.55m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.72m USD (from shortTermDebt, last quarter)
Debt = 5.43m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -233.4m USD (from netDebt column, last quarter)
Enterprise Value = 13.84b USD (14.08b + Debt 5.43m - CCE 238.9m)
Interest Coverage Ratio = -166.1 (Ebit TTM -409.3m / Interest Expense TTM 2.46m)
FCF Yield = -1.70% (FCF TTM -235.7m / Enterprise Value 13.84b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 52.89 (set to none) (Enterprise Value 13.84b / Total Assets 261.7m)
Interest Expense / Debt = 45.39% (Interest Expense 2.46m / Debt 5.43m)
Taxrate = 0.14% (-313.0k / -221.3m)
NOPAT = -408.7m (EBIT -409.3m * (1 - 0.14%)) [loss with tax shield]
Current Ratio = 3.80 (Total Current Assets 246.5m / Total Current Liabilities 64.9m)
Debt / Equity = 0.03 (Debt 5.43m / totalStockholderEquity, last quarter 192.3m)
Debt / EBITDA = 0.57 (negative EBITDA) (Net Debt -233.4m / EBITDA -409.3m)
Debt / FCF = 0.99 (negative FCF - burning cash) (Net Debt -233.4m / FCF TTM -235.7m)
Total Stockholder Equity = 340.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -157.5% (out of range, set to none)
RoE = -120.9% (Net Income TTM -412.2m / Total Stockholder Equity 340.8m)
RoCE = -118.2% (out of range, set to none) (EBIT -409.3m / Capital Employed (Equity 340.8m + L.T.Debt 5.55m))
RoIC = -112.4% (out of range, set to none) (NOPAT -408.7m / Invested Capital 363.7m)
WACC = 1.85% (E(14.08b)/V(14.08b) * Re(1.83%) + D(5.43m)/V(14.08b) * Rd(45.39%) * (1-Tc(0.00)))
Discount Rate = 1.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 93.01%
Fair Price DCF = unknown (Cash Flow -235.7m)
EPS Correlation: 27.52 | EPS CAGR: -4.47% | SUE: -4.0 | # QB: 0
Revenue Correlation: -35.79 | Revenue CAGR: -20.06% | SUE: 0.0 | # QB: 0

Additional Sources for SMMT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle